N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea
- Product Name
- N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea
- CAS No.
- 155488-25-8
- Chemical Name
- N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea
- Synonyms
- YM-220;Sograzepide;Estradiol-3-O-sulfamate;1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea;N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea;Urea, N-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]-
- CBNumber
- CB92484809
- Molecular Formula
- C28H30N6O3
- Formula Weight
- 498.58
- MOL File
- 155488-25-8.mol
N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea Property
- Boiling point:
- 723.0±60.0 °C(Predicted)
- Density
- 1.25
- storage temp.
- Store at -20°C
- solubility
- DMSO : ≥ 100 mg/mL (200.57 mM)
- pka
- 11.38±0.40(Predicted)
- form
- Solid
- color
- Off-white to light yellow
N-Bromosuccinimide Price
- Product number
- S675800
- Product name
- Sograzepide
- Packaging
- 5mg
- Price
- $925
- Updated
- 2021/12/16
- Product number
- CS-0003594
- Product name
- Sograzepide
- Purity
- 98.04%
- Packaging
- 50mg
- Price
- $1400
- Updated
- 2021/12/16
- Product number
- CS-0003594
- Product name
- Sograzepide
- Purity
- 98.04%
- Packaging
- 100mg
- Price
- $2100
- Updated
- 2021/12/16
- Product number
- INB0002926
- Product name
- YF-476
- Purity
- 95.00%
- Packaging
- 50MG
- Price
- $7500
- Updated
- 2021/12/16
- Product number
- CS-0003594
- Product name
- Sograzepide
- Purity
- 98.04%
- Packaging
- 5mg
- Price
- $250
- Updated
- 2021/12/16
N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea Chemical Properties,Usage,Production
Uses
Sograzepide is used in the treatment of gastric carcinoids or patients with chronic atrophic gastritis. Gastric receptor antagonist.
in vivo
Sograzepide?(Netazepide; YF 476; YM-220) (0.1 μmol/kg; intravenous injection) has an inhibition effect on pentagastrin-induced gastric acid secretion in anethsetized rats with an ED50 of 87?nmol/kg[1]. Sograzepide?(Netazepide; YF 476; YM-220) (intravenous injection; 10 μM/kg) inhibits pentagastrin-induced acid secretion with an ED50 value of 0.0086 μM/kg, but does not affect histamine- and bethanechol-induced acid secretion[2].Sograzepide (Netazepide; YF 476; YM-220) (intravenous injection; oral administration) in Heidenhain pouch dogs, inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner with ED50 values of 0.018 and 0.020 μM/kg, respectively [2].
IC 50
CCKBR